This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Roger M. Perlmutter (Photo: Business Wire)

Stocks in this article: MRK

“I am honored to have the opportunity to return to Merck and to lead MRL,” said Dr. Perlmutter. “Throughout my career, as both a physician and a scientist, I have drawn inspiration from Merck’s unwavering commitment to scientific excellence. Over time, this commitment has brought forth an unparalleled number of breakthrough medicines and vaccines that improve the lives of patients around the world.”

Mr. Frazier also reiterated Merck's commitment to delivering growth through innovation. “Merck continues to focus on increasing the productivity of our R&D investments to create value for patients, customers and shareholders,” said Frazier. “Under Roger’s leadership, we will continue to build and expand in key therapeutic areas, advance our promising late-stage candidates and bring forth new therapeutic candidates that will fuel our future pipeline.”

Dr. Kim joined MRL as executive vice president, Research and Development in 2001 and was appointed president of MRL in 2003. Prior to joining Merck, he served as a professor of biology at Massachusetts Institute of Technology and was also a member of the Whitehead Institute and a Howard Hughes Medical Institute investigator. While at Merck, Dr. Kim served as a member of the Council of the Institute of Medicine of the National Academy of Sciences, a member of the Board of Directors of the Whitehead Institute for Biomedical Research and as a member of the Council of the Global HIV Vaccine Enterprise.

During Dr. Kim’s tenure, Merck gained approval of more than 20 new medicines and vaccines that have sustained the company’s growth and significantly improved global health. These include JANUVIA (sitagliptin), the first DPP-4 inhibitor for type 2 diabetes; GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], the first vaccine for prevention of cervical cancer; ISENTRESS (raltegravir), the first HIV integrase inhibitor; ZOSTAVAX (zoster vaccine live), the first herpes zoster vaccine for the prevention of shingles in adults; RotaTeq (Rotavirus Vaccine, Live, Oral, Pentavalent), an oral vaccine for the prevention of rotavirus infection in infants; and VICTRELIS (boceprevir), the first oral hepatitis C protease inhibitor. As of Feb. 22, 2013, Merck has 38 candidates in late-stage clinical development (Phase II and III).

2 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs